Background:Acute myocardial infarction (AMI) is a major cause of morbidity and mortality, with significant differences in clinical presentation and outcomes between STEMI and NSTEMI. Cardiac biomarkers such as troponin I and creatine kinase-MB play a pivotal role in diagnosing AMI, particularly in female patients who often present with atypical symptoms.Objective:To compare the levels of troponin I and creatine kinase-MB in female patients with STEMI and NSTEMI and assess their diagnostic utility.Methods:This prospective study included 120 female patients diagnosed with AMI, divided equally into STEMI (n=60) and NSTEMI (n=60) groups. Serial measurements of troponin I and creatine kinase-MB were taken at admission, 6 hours, and 12 hours. Statistical analysis was performed to compare biomarker levels between groups.Results:Troponin I and creatine kinase-MB levels were significantly higher in STEMI patients compared to NSTEMI patients at all time points (p < 0.01). Peak troponin I levels were 12.8 ± 2.1 ng/mL in STEMI versus 5.2 ± 1.3 ng/mL in NSTEMI, while peak creatine kinase-MB levels were 68 ± 8 U/L in STEMI and 28 ± 6 U/L in NSTEMI. Biomarker elevation was more rapid and pronounced in STEMI patients.Conclusion:Troponin I and creatine kinase-MB levels differ significantly between STEMI and NSTEMI in female patients, reflecting the extent of myocardial injury. These findings highlight the importance of cardiac biomarkers and suggest the need for sex-specific diagnostic thresholds to improve accuracy and outcomes in women with AMI.